AstraZeneca
British-Swedish pharma with +18% growth in 2024 ($54.1B revenue). Strong in oncology, respiratory, and cardiovascular medications.
Services Offered
Our Take
AstraZeneca had one of the best 2024 performances among Big Pharma - 18% revenue growth. They're particularly strong in cancer drugs and respiratory treatments. Their AZ&Me program can help significantly with costs. If you have cancer, lung disease, or heart conditions, check if your medication qualifies for AZ&Me assistance.
Pros
- ✓+18% revenue growth (2024) shows drug effectiveness
- ✓Strong oncology pipeline
- ✓Respiratory expertise
- ✓AZ&Me patient assistance program
- ✓Active R&D investment
Cons
- ✗Specialty drugs expensive without assistance
- ✗Complex insurance navigation
- ✗Some supply constraints
- ✗Less consumer brand awareness
Pricing Details
AZ&Me prescription savings program provides assistance to eligible patients. Covers most AstraZeneca medications.
Best For
- • Cancer treatment
- • Respiratory conditions (asthma, COPD)
- • Heart disease
Coverage
- 📍 Global
Accreditations
- ✓FDA approved
Trust Indicators
Years in Business
25+
Last verified: December 21, 2024
⚠️ Important
Always verify pricing and details directly with the provider. Prices shown are estimates based on our research as of December 2024 and may have changed.
This information is for educational purposes only and does not constitute medical advice. Consult with qualified healthcare professionals before making medical decisions.
We may earn a commission if you use our links, but this does not affect our editorial opinions or the information presented.
Opens in new window • direct link